Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $19.50

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $19.50.

A number of analysts have issued reports on IMMX shares. HC Wainwright lifted their target price on shares of Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Morgan Stanley began coverage on shares of Immix Biopharma in a research report on Wednesday, March 25th. They set an “overweight” rating and a $20.00 target price on the stock. Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Mizuho increased their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $23.00 target price on shares of Immix Biopharma in a research report on Friday, March 27th.

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMMX. Allworth Financial LP acquired a new stake in Immix Biopharma in the 4th quarter worth approximately $30,000. Mathes Company Inc. acquired a new stake in Immix Biopharma in the 4th quarter worth approximately $56,000. Balyasny Asset Management L.P. acquired a new position in Immix Biopharma in the 4th quarter valued at $67,000. Kera Capital Partners Inc. acquired a new position in Immix Biopharma in the 4th quarter valued at $68,000. Finally, Velan Capital Investment Management LP grew its stake in Immix Biopharma by 40.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock valued at $73,000 after buying an additional 10,000 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Price Performance

Shares of IMMX stock opened at $9.00 on Friday. The firm has a market cap of $489.69 million, a P/E ratio of -9.78 and a beta of 0.12. The stock’s 50-day moving average is $9.32 and its two-hundred day moving average is $7.29. Immix Biopharma has a fifty-two week low of $1.87 and a fifty-two week high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. As a group, research analysts expect that Immix Biopharma will post -0.74 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.